Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Receivables - Other (2016 - 2024)

Avalo Therapeutics filings provide 9 years of Receivables - Other readings, the most recent being -$600000.0 for Q4 2024.

  • On a quarterly basis, Receivables - Other fell 20.0% to -$600000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was -$600000.0, a 20.0% decrease, with the full-year FY2024 number at $611000.0, up 349.26% from a year prior.
  • Receivables - Other hit -$600000.0 in Q4 2024 for Avalo Therapeutics, down from $998000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $4.3 million in Q3 2020 to a low of -$600000.0 in Q4 2024.
  • Median Receivables - Other over the past 5 years was $1.3 million (2022), compared with a mean of $1.4 million.
  • Biggest five-year swings in Receivables - Other: surged 1958.27% in 2020 and later plummeted 1766.67% in 2024.
  • Avalo Therapeutics' Receivables - Other stood at $2.2 million in 2020, then surged by 69.34% to $3.7 million in 2021, then crashed by 48.68% to $1.9 million in 2022, then crashed by 126.06% to -$500000.0 in 2023, then decreased by 20.0% to -$600000.0 in 2024.
  • The last three reported values for Receivables - Other were -$600000.0 (Q4 2024), $998000.0 (Q3 2024), and -$100000.0 (Q2 2024) per Business Quant data.